Early and Mid-Term Outcomes of Transcatheter Aortic Valve Replacement Using the New Generation Self-Expanding Corevalve Evolut R Device

• Published in: Structural heart (Online) Vol. 2; no. 3; pp. 229 - 234
• Main Authors: Todaro, Denise, Barbanti, Marco, Picci, Andrea, Costa, Giuliano, Di Simone, Emanuela, Gulino, Simona, Capranzano, Piera, Pilato, Gerlando, La Spina, Ketty, Deste, Wanda, Indelicato, Antonino, Giannazzo, Daniela, D’Arrigo, Paolo, Portelli, Maria Cristina, Capodanno, Davide, Immè, Sebastiano, Tamburino, Claudia, Patanè, Martina, Sgroi, Carmelo, Tamburino, Corrado
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 04.05.2018; Taylor & Francis
• Subjects: Aortic stenosis; CoreValve Evolut R; new device; transcatheter aortic valve replacement; transcatheter heart valve; transcatheter aortic valve replacement; Aortic stenosis; transcatheter heart valve; new device; CoreValve Evolut R
• ISSN: 2474-8706; 2474-8714
• DOI: 10.1080/24748706.2018.1440097

To assess early and mid-term efficacy of transcatheter aortic valve replacement (TAVR) using the new-generation CoreValve Evolut R (Medtronic Inc., Galway, Ireland). This is a prospective, single-center study. All consecutive patients undergoing TAVR with 23-, 26-, 29-, 34-mm Evolut R valve were included. In a secondary analysis, patients undergoing Evolut R implantation were compared using the propensity score method with a historical cohort of patients who underwent CoreValve implantation in our institution. From March 2015 to September 2017, a total of 320 patients with a median age of 81.1 years (IQR 77–84) and mean STS score of 4.9 ± 3.1% were treated. Device success was obtained in 300 patients (93.8%). Effective recapture and repositioning of the valve due to initial suboptimal deployment was accomplished in 40 patients (12.5%). Post-TAVR transthoracic echocardiogram showed a reduction in mean gradient from 49.1 ± 18.2 mmHg to 7.6 ± 0.4 mmHg (p < 0.001). Moderate paravalvular regurgitation (PVR) was observed in 4.2% patients. No patient had severe PVR. At 30-day, all-cause and cardiovascular mortality rates were 2.2% and 1.9%, respectively; disabling stroke occurred in 5 patients (1.6%). Life-threatening and major bleeding occurred in 16 (5.0%) and 42 (13.1%) patients, respectively. Pacemaker implantation rate was 12.6%. Compared with the CoreValve, Evolut R use was associated with higher device success (92.8% vs. 79.7%, p < 0.001) and lower rates of moderate or severe PVR (2.1% vs. 14.4%, p < 0.001), minor vascular complications (4.9% vs. 14.5%, p < 0.001), and pacemaker implantation (13.5% vs. 21.0%, p = 0.026). In this prospective, single-center study, TAVR using the new-generation self-expanding Evolut R system, was associated with high device success rate, excellent hemodynamics, and low early complications rates.